Seeking Alpha

Pharmacyclics (PCYC +10.2%) continues its climb again today on the back of the FDA's orphan...

Pharmacyclics (PCYC +10.2%) continues its climb again today on the back of the FDA's orphan status approval of its chronic lymphocyctic leukemia treatment. Analysts are projecting blockbuster sales for the cancer drug, including Brean Murray, who initiated the shares with a Buy earlier today on the back of the announcement.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)